Moderna, Medison partner on Moderna's COVID-19 vaccine

By The Science Advisory Board staff writers

June 7, 2021 -- Moderna and Medison Pharma announced that they are entering into a marketing agreement for Moderna's COVID-19 vaccine across central Europe and Israel.

The commercialization agreement will apply to about 20 countries in central and Eastern Europe.

Financial details of the agreement were not disclosed.

In other Moderna news, the company has filed for Health Canada authorization for the use of its COVID-19 vaccine in adolescents ages 12 to 18; it has also applied for conditional marketing approval of the vaccine for this age group in the European Union.

Moderna initiates rolling BLA for COVID-19 vaccine
Moderna has started the rolling submission process with the U.S. Food and Drug Administration for a biologics license application (BLA) for the use of...
Thermo, Moderna ink COVID-19 vaccine manufacturing deal
Moderna has signed a deal with Thermo Fisher Scientific to provide manufacturing services and supply packaging for its COVID-19 vaccine.
Moderna vaccine 100% effective for teens
Moderna announced its phase II/III study of its COVID-19 vaccine in adolescents has met its primary immunogenicity endpoint with no cases of COVID-19...
Moderna inks South Korean mRNA vaccine collaborations
Moderna has inked two memoranda of understanding agreements with South Korea for messenger RNA (mRNA) vaccine research and manufacturing in that country.
Japan approves Moderna COVID-19 vaccine
Japan's Ministry of Health, Labour, and Welfare recently approved Moderna's COVID-19 vaccine, and distribution in the country by Takeda will begin immediately.

Copyright © 2021

Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter